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Evidence to address a scientific question is generated through the design of research aiming to answer it. Probably
the most often sought design in epidemiologic research is a randomized clinical trial that offers the advantage of controlling for
confounders, which may influence the trial outcome. In contrast, observational study designs test hypotheses when clinical
trials are difficult to implement. The interest in clinical trials has led to an explosion of manuscripts testing interventions in
health care, often yielding interesting results albeit in statistically underpowered samples. Thus, the clinician faces the
challenge of making sense of multiple studies that produce results of variable strength when attempting to assess the evidence
supporting a treatment. Meta-analytic methods represent an alternative to assess the evidence by pooling the results from
multiple studies to increase statistical power. This manuscript describes considerations for planning and implementing meta-
analysis in oral medicine. (Oral Surg Oral Med Oral Pathol Oral Radiol 2013;116:194-202)Oral medicine offers non-surgical treatment (with the
exception of biopsies) for multiple conditions that affect
the orofacial region. The myriad of disorders treated by
oral medicine experts include oral manifestations of
dermatologic disorders, orofacial pain, salivary gland
disorders, and oral care of medically complex patients.
Although extensive research has been done in some
areas, evidence-based treatment of certain disorders
remains limited to a small number of clinical studies. A
relevant example is the management of burning mouth
syndrome, which is supported by less than a handful of
interventions tested in clinical trials.1 Another example,
therapy for disorders such as oral lichen planus (OLP),
has been traditionally restricted to the topical applica-
tion of corticosteroids, and few trials have assessed the
impact of corticosteroid formulation, potency, and
frequency of application on outcomes in OLP subjects.2
Moreover, the selected primary outcome from a recent
Cochrane review was resolution of pain, used as
a surrogate marker for clinical improvement. Questions
may rise about the concordance of this surrogate with
the erosive presentation of OLP, which may not always
be symptomatic. Meta-analysis is a critical tool devel-
oped by social scientists that applied to clinical medi-
cine is valuable to steer decision-making and
formulation of clinical guidelines for the treatment and
diagnosis of disease. This manuscript provides a brief
illustration of relevant considerations authors shouldaDepartment of Oral Medicine, University of Pennsylvania School of
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some examples of the application of this technique in
oral medicine.
DEFINITION
A meta-analysis is the statistical analysis of a large
collection of results from individual studies to integrate
their ﬁndings. This method produces an estimate of the
average treatment effect. In addition, an evaluation of
the variability across studies is performed to recognize
within study and between study differences.3 These
estimates may be useful to generate additional analyses,
namely sensitivity analysis and bias assessment, and
assist the investigators in evaluating hypothesis
regarding the sources of variability. The phases of any
meta-analysis should be planned a priori and based on
speciﬁc hypothesis or aims that the investigators would
like to explore.4 This is particularly important to narrow
the analysis to the questions of interest, rather than
“mining” the data for statistically signiﬁcant results.
The terms “meta-analysis” and “systematic review”
are occasionally used interchangeably in the literature.
However, they refer to 2 complementary but different
processes. A systematic review is deﬁned as a methodic
review of the literature, often accompanied by a scale or
grading algorithm that assigns values to the presence or
absence of evidence (deﬁned by the publication ofStatement of Clinical Relevance
This manuscript offers an overview of methodologic
considerations in planning systematic reviews and
meta-analysis, and provides examples of recent work
in oral medicine and lessons learned for future
studies.
Fig. 1. Example of graphic/forest plot. The black boxes
represent the weight of individual studies, and the horizontal
lines are the 95% CI of the summary estimate. A risk ratio of
less than 1 represents a protective effect. A risk ratio greater
than 1 represents increase risk of developing the outcome in
the intervention group.
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reports) that answers the question posed by the
systematic review. Systematic reviews minimize bias
and errors that can occur with narrative reviews, using
a well thought and structured search strategy that will
include all the existing literature in a particular topic.4,5
Systematic reviews may further analyze the data toward
a meta-analysis or may be restricted to qualitative
grading of the evidence. The decision to pursue addi-
tional statistic analysis rests on the investigators after
considering the characteristics of the studies reviewed,
such as outcome deﬁnition and measurement, subject
population, study design, presence of bias, and clarity
of outcome reporting. Meta-analysts should carefully
consider how the data will be pooled, as the simple
aggregation of measures is not appropriate. Discussion
of network meta-analysis, a method used to compare
the results of studies that share a common treatment in
similar populations (not in a randomized clinical trial),
extends beyond the scope of this manuscript.RATIONALE
Meta-analysis has the advantage of encompassing
large subject numbers, increasing the ability to detect
small but clinically important effects. The ﬁnding
of signiﬁcant inter-study differences may generate
new hypotheses for future research, and analysis
of group/subset effects increases precision.4,5 Sup-
porting arguments for performing a meta-analysis
include the increase in power and precision of the
calculated estimates, quantiﬁcation of effect sizes, and
the assessment of the consistency of results across
trials (Figure 1). The most convincing argument for
carrying out a meta-analysis is in the presence of
apparently similar clinical studies reporting results
with different effect sizes.6PRINCIPLES OF META-ANALYSIS
The underlying basis of a meta-analysis is the integra-
tion of summary statistics among studies. Subjects
across studies are not directly compared to each other,
and details of the design and implementation of the
study are evaluated independently.5 The investigators
set the inclusion criteria for studies to be considered.
Therefore, they are keenly involved in the assessment
of each study prior to performing the analysis. A second
principle involves the weighting of studies in the
overall analysis, usually following estimates of preci-
sion (by the inverse variance method) and study sample
size. To illustrate this process, a graphic representation
(forest plot) is generated (Figure 1). This principle has
been controversial as studies with more subjects often
inﬂuence the variability of the ﬁnal effect size,
demanding careful scrutiny of study characteristics,including design, allocation, blinding, implementation,
and outcome deﬁnition.
META-ANALYSIS OF RANDOMIZED
CONTROLLED CLINICAL TRIALS
Randomized controlled trials provide evidence on the
efﬁcacy of interventions on separate groups, usually
divided into “active” or intervention group and a
group treated with a placebo. The randomization
scheme should balance the intervention and placebo
groups in important known and unknown character-
istics that may affect the association between the
intervention and outcomes. An advantage of meta-
analysis of randomized clinical trials is the presumed
low incidence of bias in these studies. In reality,
complete avoidance of bias is challenging and many
trials in oral medicine include signiﬁcant bias.
Nevertheless, these studies offer summary estimates of
effect that can be translated into relative risks (RR) or
odds ratio (OR) and are easily interpretable by clini-
cians who want to see a quantitative difference
between groups.7 The evaluation of study quality and
presence of bias is peremptory when performing
a meta-analysis. Bias assessment provides an estimate
of study quality and allows for sensitivity analysis
within groups of studies with greater or lesser quality.
Methods for bias assessment include appraisal of the
reporting of the trial, how randomization was done, who
was responsible for randomizing subjects, and whether
allocation was preestablished, among other items.
A widely used scale to assess bias in randomized clinical
trials is the JADAD scale, developed and validated in
several settings (Figure 2).8 Additional tools exist to
assess the methodologic quality of meta-analysis, (see
section on quality evaluation of meta-analysis).9
Fig. 2. Items considered in the JADAD scale for quality eval-
uation of randomized clinical trials. Adapted from Ezzo et al.8
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STUDIES
Observational studies include cohort and case control
designs. The former can occur as prospective or retro-
spective studies, and focus on follow up of a population
that is divided in 2 groups: exposed or not exposed. The
outcome is the incidence of subjects who develop the
disease during follow up. Retrospective chart reviews
are usually considered retrospective cohort designs that
explore the association between exposure and occur-
rence of disease. Case control designs offer a different
approach, whereby subjects with the disease are
selected and a control group of subjects without the
disease is used for comparison. Both cohort and case
control designs have their own strengths and are used
when randomized clinical trials are difﬁcult to imple-
ment or when ethical issues surrounding implementa-
tion of a randomized clinical trial are considerable. An
example of such case is the controversy surrounding
bacterial endocarditis of odontogenic origin and the
efﬁcacy of antibiotic prophylaxis. A randomized clin-
ical trial to answer this question would probably be
challenged by a Human Subjects Research Committee
because of the increased risk to participants who are
placed in the “placebo group.” In addition, the expense
of performing such trial to achieve the required sample
size to demonstrate efﬁcacy is prohibitive. Hence, the
evidence to address this question is limited to obser-
vational and animal studies.
The meta-analysis of observational studies is
controversial, and criteria for reporting and evaluating
these has only been available in the last 5 years.9
A critical issue is the lack of valid approaches to the
assessment of quality of observational studies. In
contrast to randomized clinical trials, no study quality
scale has been thoroughly tested and validated forassessment of observational studies. Only one scale, the
Newcastle Ottawa Scale has gone through initial face
and content validity testing, and further validation is in
progress.10 Observational studies often fail to report
clear effect estimates, or grouping of study measures
from different studies is not feasible due to inherent
differences in methods or inclusion criteria. In this
scenario, meta-analysts are left to deal with quantitative
comparisons of differences in means or proportions of
subjects with the outcome of interest, which yields
a mean standard difference estimate. This approach
requires additional data abstraction and calculation of
standard deviation and medians from each study.
Abstraction of this data may be difﬁcult due to lack of
reporting or to the requirement of extensive calculations
from the information given in the manuscript. Even
with this data, the clinical signiﬁcance of proportional
changes in measures requires validation from previous
studies with prospective trials. Analysis of diagnostic
and prognostic methods can be achieved with meta-
analysis, and these techniques require additional
considerations beyond the scope of this manuscript.
SELECT META-ANALYSIS IN ORAL MEDICINE
Meta-analysis has been employed in the ﬁeld of oral
medicine since 2001 when human papilloma virus
(HPV) was identiﬁed as risk factor for oral squamous
carcinoma.11 Since then increased meta-analytic atten-
tion to therapeutic areas in oral medicine has occurred
(Table I). For example, an evaluation of the evidence on
the efﬁcacy of topical corticosteroids in the treatment
for OLP failed to identify any randomized clinical trial
comparing a corticosteroid to placebo.2 This meta-
analysis also highlighted the absence of studies
comparing dosing strategies of topical corticosteroids
and reported weak evidence supporting the efﬁcacy of
pimecrolimus. In addition, most of the 28 studies
reviewed had a high risk of bias. Another study
exploring the effectiveness of surgical interventions
versus systemic corticosteroid therapy for the periodic
fever, aphthous stomatitis, pharyngitis and adenitis
(PFAPA) syndrome reported surgical options as being
the choice for long-term resolution of symptoms.14
PFAPA is one of a handful of immune mediated
syndromes that present with recurrent severe aphthous-
like oral ulcerations. The treatment for this syndrome is
controversial, and although topical/systemic cortico-
steroid therapy aborts acute symptoms, no conclusive
evidence remains regarding long-term resolution. Other
interesting reviews explored the efﬁcacy of antiviral
therapy for the prevention of primary herpetic gingi-
vostomatitis and recurrent herpes labialis.13,18 Marginal
beneﬁt of antiviral therapy for patients with primary
infection was reported, and only 2 studies qualiﬁed to
be included in the analysis due to reporting and
Table I. Select meta-analysis studies published in oral medicine topics in the last 8 years
Author, year Outcome
No. of studies
included Total No. of subjects Interventions or exposures Conclusion
Zakrzewska,
20051
Effectiveness of interventions for burning
mouth syndrome (BMS)
Pain relief and global assessment of
change
9 470 (BMS) Antidepressants, anticonvulsants,
behavioral, a-lipoic acid, hormone
replacement, analgesics
Limited evidence. Few trials with
acceptable methodological quality
Zintzaras,
200512
Risk of developing lymphoma in
autoimmune disorders
20 8700 cases with Systemic lupus, 95,104
cases with rheumatoid arthritis, 1300
with primary Sjögren syndrome
Non-Hodgkin lymphoma Association of lymphoma with several
autoimmune disorders
Nasser, 200813 Efﬁcacy of systemic acyclovir to treat
primary gingivostomatitis
Reduction of number of oral lesions,
difﬁculty eating or drinking, pain,
fever (primary)
reduced hospital admission for
children under 6 years of age, quality
of life, patient or parental satisfaction
(secondary)
2 92 subjects younger than 6 years with
primary herpetic gingivostomatitis
Systemic acyclovir Weak evidence to support the use of
systemic acyclovir
Peridis, 201014 Comparison of medical and surgical
therapies for PFAPA, effectiveness of
tonsillectomy (with/without
adenoidectomy), effectiveness of other
medical therapies
14 374 (PFAPA) Antibiotics, cimetidine, corticosteroids,
tonsillectomy with/without
adenoidectomy
Surgical therapy (tonsillectomy and
adenoidectomy is the most effective
for long-term resolution of symptoms)
Liu, 201015 Effectiveness of acupuncture to treat
trigeminal neuralgia (TGN)
Categorical pain relief, functional scale
12 920 (TGN) Acupuncture (manual or electric) Weak evidence to support the use of
acupuncture in the management of
TGN
Thongprasom,
20112
Effectiveness of topical treatment for oral
lichen planus (OLP)
Oral mucosal pain (primary), degree of
erosion, erythema, reticulation
(secondary)
28 1205 (OLP) Topical corticosteroids, cyclosporin,
calcineurin inhibitors, aloe vera
No comparison among topical
corticosteroids, weak evidence
supporting topical cyclosporin, or
calcineurin inhibitors
Yang, 201116 Efﬁcacy of non-antiepileptic medications
to treat TGN
Pain relief, decreased trigeminal
neuralgia score (Number of attacks per
day and intensity) (primary)
Adverse effects in 2 weeks, improvement
in pain or TN score at 12 weeks
(secondary)
4 139 (TGN) Carbamazepine, pimozide, proparacaine
hydrochloride, tocainide, tizanidine
Insufﬁcient evidence to support beneﬁt
from non-antiepileptic medications to
treat TGN
(continued on next page)
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198 Pinto August 2013methodological issues. In contrast to the acute presen-
tation, analysis of 10 studies supported the beneﬁt of
systemic acyclovir and valacyclovir for the prevention
of recurrent disease.
Perhaps one of the areas that has received more
attention from a meta-analysis perspective is orofacial
pain. Multiple studies, mostly published in the last
3 years, have addressed issues such as efﬁcacy of
medications for the treatment of trigeminal neuralgia,
temporomandibular disorders, and acute and chronic
facial pain management.15-17,19-24 Among these, a paper
published in 2010 failed to identify a beneﬁt of
systemic corticosteroids in preventing post-herpetic
neuralgia, another common complication that oral
medicine clinicians manage in the facial area.19 Select
additional manuscripts related to oral medicine deal
with the appraisal of therapeutic options for head and
neck cancer, the association between autoimmune
disease and the occurrence of lymphoma, and the efﬁ-
cacy of treatment of salivary hypofunction.12,25-29 The
report describing the association between autoimmune
disease and lymphoma is of importance because it
concludes that the risk of developing lymphoma in
patients with conditions such as Sjögren syndrome
appears to be low, contrary to past belief.12
Meta-analysis may offer conclusions that challenge
trends in clinical practice due to lack of well-designed
studies rather than to evidence of non-efﬁcacy of the
intervention. These studies may also offer important
information on disease etiology or collate information
from other systematic studies.11 The clinician is alerted
to carefully evaluate these manuscripts to understand
the relevance of the conclusions and implications to
practice. The lesson learned from these and other
manuscripts is that key factors to consider when eval-
uating studies are the presence of bias and the reporting
of allocation strategy. They also highlight the broad gap
of scientiﬁc support for many interventions that are
accepted as standard of care and the need for stan-
dardization of the methodology and reporting of
epidemiologic research.
METHODOLOGIC CONSIDERATIONS
The value of a meta-analysis lies in its strict protocol
and reporting criteria. Several issues are relevant to
consider during planning and developing the analysis,
as they may inﬂuence its outcome. The following
section will discuss pitfalls and mistakes that can occur
in several stages of a meta-analysis. The reader is again
reminded that a written protocol must be formulated
among the investigators that will serve as a guide to
solve any issue that may arise during the implementa-
tion of the project. This protocol requires formulation of
a speciﬁc question to be answered by the analysis, and
deﬁnition of the desired outcome to be measured.3
Fig. 3. Hypothetical funnel plot to explore publication bias.
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Although the concept of meta-analysis is more than 30
years old, its use has grown dramatically in the last 15
years due to the advent of the internet, the registration of
clinical trials in centralized databases, the appearance of
electronic search engines, and the systematization of
meta-analytic procedures in computer programming.
Sources for manuscripts include search engines such as
Medline-PubMed/Ovid, ISI Web of Knowledge,
EBSCO, Evidence BasedMedicine Reviews (EBMR)e
Cochrane Database of Systematic Reviews, and the
Cochrane Clinical Trial Registry. The National Insti-
tute of Dental and Craniofacial Research mandates
registration of all federally funded clinical trials in the
National Institutes of Health website, and many
Institutional Review Boards in the United States and
abroad require registration of a clinical trial in this
site. Therefore, multiple sources of scientiﬁc literature
are readily available for potential meta-analysts. Some
of these go back as far as 1950, and are usually
updated on a monthly or biweekly basis. Even when
potential sources are identiﬁed, investigators should
consult a librarian or informationist for assistance in
setting the search terms. Depending on the search
engine, this process may take several days or weeks to
establish, as combinations of terms, MeSH terms, and
keywords is often required in an exhaustive process.
This process may take weeks because the validity of
the meta-meta-analysis depends on the collection of all
published and unpublished evidence, or of a signiﬁ-
cant sample of all existent evidence. If manuscripts or
other evidence (see gray literature below) are missed,
this will undermine the strength of the analysis.
Authors should also extend their search to additional
sources, like data not published in peer reviewed
journals, conference abstracts, doctoral thesis, and
polling of experts in the ﬁeld for suggestions of
relevant manuscripts (gray literature).30 The fact that
manuscripts with negative results tend not to be
submitted or published is termed publication bias, and
may amplify an optimistic estimate of effect. This will
be discussed in detail in the section describing
publication bias. Hand searches of specialty journals
published in recent years helps to assure completeness
of the search process. Documentation of an attempt by
the study team to search the gray literature is imper-
ative in any meta-analysis.
STUDY SELECTION
Selection of studies is based on eligibility criteria and
outcomes as deﬁned in the protocol. All manuscripts
produced by the search and their abstracts are inde-
pendently reviewed by at least 2 of the investigators
using piloted data abstraction forms, who then note
whether to include the study in the ﬁnal review. Theinvestigators should be blinded to study outcomes to
decrease bias as the decision of study inclusion involves
study methods and procedures. Obviously, this will not
be possible if a speciﬁc outcome reporting forms part of
the inclusion criteria. Discrepancies between investi-
gators regarding inclusion of studies are resolved by
a method stated in the protocol. This may be by
consultation with a third investigator, by consensus
between the 2 original abstractors, or by an independent
review of the complete manuscript. The selection
process invariably reduces the number of studies to
include in the ﬁnal analysis. At this point, the investi-
gators proceed to evaluate the quality of the studies and
decide if a meta-analysis is feasible, or if differences
among studies and quality of studies preclude further
evaluation. Besides the scales mentioned previously,
study quality assessment is achieved by exploring
individual factors associated to the type of study
reviewed, including blinding and randomization.
CONSIDERATIONS FOR AGGREGATING
DATA
Prior to aggregating data from studies, factors such as
differences in patient population, treatment allocation,
follow up, and outcome measurement need to be
considered. Summary estimates are reported in most
studies, and authors may want to request raw or indi-
vidual patient data if available. This is germane to
conﬁrm marginal ﬁndings in the analysis, or to calculate
stratiﬁcation of outcomes not performed in the original
study. Statistical issues concerning the aggregation of
summary estimates deal with accounting for heteroge-
neity, study quality and choice of measure to report
(i.e., RR vs. OR vs. mean standard difference).31
STUDY HETEROGENEITY
Heterogeneity among reviewed manuscripts can be
initially observed in the initial graphic output and 95%
conﬁdence intervals (CIs) (Figure 1). Non-overlap of
Fig. 4. Forest plot of random effects analysis and heterogeneity estimates.
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statistic methods to assess heterogeneity include the
calculation of a X2 test, which has low power with small
groups of studies, and the better I2, that produces
a percentage of the heterogeneity attributed to differ-
ences between studies. Increased heterogeneity is of
concern, and a high percentage (>60% in the I2 esti-
mate) demands for additional exploration of sources of
heterogeneity, such as subgroup and sensitivity anal-
yses. Elucidation of the sources of heterogeneity will
require a detailed evaluation of study effects under
different circumstances such as diverse subject groups,
geographic area, or study drug dosing.
PUBLICATION BIAS
Investigators may be concerned about the over report-
ing of studies with positive results, as authors are not as
eager to submit papers with negative ﬁndings. This may
“bias” the body of literature toward positive ﬁndings,
even when the magnitude of these ﬁndings may not be
so strong.31 Standard estimation of publication bias is
performed by using a funnel plot, (Figure 3) a graphic
representation of study precision, provided by measures
of variance (1/V) or standard error on the y-axis and
effect estimates on the x-axis. The resulting plot will
produce an inverted funnel appearance, with smaller
studies being spread at the base and larger studies
narrowing toward the top.
Study size may have a strong impact on estimation of
publication bias. Bias could occur in studies with low
quality, or in smaller studies reporting larger treatment
effects. The presence of asymmetry in the funnel plot does
not necessarily indicate the presence of bias, as additional
sources that should be evaluated during study assessment
include study heterogeneity, poor choice of effect
measure, chance, and methodological issues with subjectselection.32 Additional statistical methods exist to eval-
uate publication bias (i.e., metaregression, Begg’s and
Egger’s tests), which are beyond this manuscript.31,33
ANALYSIS e FIXED VERSUS RANDOM EFFECTS
Once all study characteristics have been entered in
a statistics program, the meta-analysis can be done by
ﬁxed or random effects processes. The forest plot
(Figures 1 and 4), contains the effect measures from
all studies, their weight in the overall analysis, and the
summary estimate with its corresponding 95% CI.
Often measures of heterogeneity such as the Q
statistic, X2, or the I2 are also reported within the
forest plot.34 The Q test provides information about
the presence of heterogeneity but does not offer
a quantitative evaluation of the extent of this hetero-
geneity. The I2 offers the advantage of providing
a quantitative assessment of the heterogeneity in
effect sizes that are due to between study variability.
By deﬁnition, the ﬁxed effects analysis assumes there
is a ﬁnite number of studies (the investigators are sure
they have captured all published and unpublished
material), the differences among studies are due to
chance, and the effect of therapy is equivalent across
all studies. Random effects meta-analysis is more
conservative. The assumptions under this approach
are that studies sampled constitute a random sample
of all existent studies, and that there is heterogeneity
and variability between studies. Random effects
analysis assigns less weight to big trials.34 There is no
consensus on which approach is best, and often meta-
analysts perform both to explore between study
heterogeneity. Both approaches yield similar results
when there is no signiﬁcant heterogeneity and a
similar pooled effect, and disparate results when
there is marked asymmetry.
OOOO REVIEW ARTICLE
Volume 116, Number 2 Pinto 201PUBLICATION AND QUALITY STANDARDS
FOR SYSTEMATIC REVIEWS AND META-
ANALYSIS
Substantial advances have been done in the formulation
of requirements for reporting and evaluating systematic
reviews and meta-analysis. These have resulted from
consensus meetings with experts in the ﬁeld, producing
precise elements that must be included in the reporting
of meta-analysis.35e37 These include having access to
the study protocol, a detailed description of the search
strategy, including sources consulted, assessment of
bias and heterogeneity in the studies to be included, and
the formulation of pre-speciﬁed analysis to follow
(stated in the protocol). The most recent standards
include the Assessment of Multiple Systematic
Reviews (AMSTAR) and the Preferred Reporting Items
for Systematic Reviews and Meta-analysis (PRISMA)
statements, which provide guidelines to reviewers, and
authors of meta-analytic manuscripts.36,37
CONCLUSIONS
Meta-analysis is a useful statistical approach to
summarize the existent evidence on a clinical or
scientiﬁc question. Rather than being a simple tool,
meta-analysis requires meticulous consideration of the
study in question, careful formulation of a study
protocol to be followed by all investigators, and at least
duplicate independent data abstraction. Evaluation of
study characteristics and biological signiﬁcance of
pooling estimates from different studies is not a trivial
process, and marks the transition from a systematic
review to a meta-analysis. The number of published
meta-analysis in oral medicine has increased in the last
5 years, albeit limited by the quality of accessible
studies, and the availability of funding. In lieu of major
clinical trials, oral medicine investigators may beneﬁt
from the meta-analysis of small well-designed trials to
evaluate the state of the science in our ﬁeld.
The author thanks Susan Ellenberg PhD, Associate Dean for
Clinical Research, University of Pennsylvania Perelman
School of Medicine for her careful review and suggestions
during the writing of this manuscript.
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